Replies to post #216190 on Biotech Values

[dangerM]

RXDX / ROG

... this acquisition really makes sense. I'v been following them and on the pro side they do not only have their drug pipeline (entrectinib being CNS-active, RXDX-105 being the outstanding candidates), but also own some testing suite:

https://ignyta.com/providers/dx-molecular-diagnostic-cancer-testing/

Ignyta’s Trailblaze™ diagnostic programs leverage both Immunohistochemistry (IHC) screening and Next-Generation Sequencing (NGS) to identify tumors that may respond to entrectinib. First, IHC is used to measure protein expression levels for NTRK1, NTRK2, NTRK3, ROS1, and ALK. Then the presence of a gene rearrangement of interest is confirmed by NGS. Our clear and concise output report puts actionable results in your hands.

Cf. also what was written very early today about rumors (start as diagnostic and not a drug company): https://finance.yahoo.com/news/exclusive-u-cancer-drugmaker-ignyta-012810562.html

So there is something in for both Roche's pharmaceutical and diagnostic arm.


In other news:

https://www.bloomberg.com/news/articles/2017-12-22/roche-to-buy-u-s-cancer-drugmaker-ignyta-for-1-7-billion

https://uk.reuters.com/article/us-ignyta-m-a-roche/roche-to-buy-u-s-cancer-drugmaker-ignyta-for-1-7-billion-idUKKBN1EG0HH

[Titan V]

RXDX fun fact—It was born out of a reverse merger into an oil and gas company!

NTRK has been a successful TKR to pursue. Both $LOXO and $RXDX incorporated in 2013 and billion dollar co's 4 years later. RXDX born out of a reverse merge into an oil and gas company!

— M (@bio_clouseau) December 22, 2017